DOJ Cannabis Enforcement Shift: Policy Changes and Legal Impact

Executive Summary

The Department of Justice has signaled a fundamental shift in its approach to cannabis enforcement, with immediate implications for pending federal litigation and state-level regulatory disputes. The policy change, referenced in recent filings before the U.S. Court of Appeals for the Ninth Circuit, affects how federal prosecutors approach conflicts between state cannabis licensing regimes and the Controlled Substances Act. This shift comes as the DEA moves forward with rescheduling proceedings that would reclassify cannabis from Schedule I to Schedule III under 21 U.S.C. § 812, fundamentally altering the legal landscape for operators, municipalities, and patients. The Los Angeles licensing challenge now pending before the Ninth Circuit represents a test case for how federal courts will interpret DOJ's new enforcement posture in disputes involving local social equity programs, residency requirements, and competitive licensing frameworks. With over $30 billion in annual legal cannabis sales across 38 states, the DOJ's enforcement priorities directly impact capital allocation, MSO expansion strategies, and the viability of state regulatory programs that have operated in tension with federal prohibition since California legalized medical cannabis in 1996.

Why This Matters

The DOJ's enforcement shift affects every stakeholder in the $30 billion U.S. cannabis industry, from cultivators and dispensaries to patients, investors, and municipal regulators. For operators, federal enforcement policy determines whether state-licensed businesses face prosecution under 21 U.S.C. § 841 (manufacturing and distribution) or can operate with relative certainty. Multi-state operators have invested over $15 billion in cannabis infrastructure since 2020, with valuations tied directly to regulatory risk. A formal DOJ policy of non-interference with state-compliant operators would unlock institutional capital currently sidelined by federal illegality. Patients relying on medical cannabis programs in 38 states face uncertainty when federal enforcement priorities shift. Approximately 6.7 million registered medical cannabis patients depend on state-legal supply chains that technically violate federal law. DOJ enforcement discretion determines whether these supply chains remain viable. Municipalities implementing social equity licensing programs, like Los Angeles, have structured frameworks assuming federal non-interference with state-compliant operators. The Los Angeles program prioritizes applicants from communities disproportionately impacted by cannabis prohibition, with over 400 social equity applicants competing for limited retail licenses. Federal enforcement policy determines whether these local equity initiatives survive legal challenges based on dormant Commerce Clause theories or federal preemption under the Supremacy Clause. State tax revenues depend on continued federal forbearance. California collected $1.1 billion in cannabis tax revenue in 2025, funding education, environmental restoration, and public health programs. Twenty-one states now derive over $100 million annually from cannabis taxes. A return to aggressive federal enforcement would collapse these revenue streams. The financial sector watches DOJ policy closely. Banks and credit unions serving cannabis clients operate under FinCEN guidance issued in 2014, which relies on DOJ enforcement priorities outlined in the now-rescinded Cole Memorandum. Approximately 800 financial institutions file Marijuana-Related Business (MRB) Suspicious Activity Reports, serving over 70% of state-licensed operators. Shifts in DOJ enforcement policy directly impact banking access for the entire industry.

Background and History

Federal cannabis enforcement policy has oscillated between aggressive prohibition and selective forbearance for over five decades, creating a complex legal landscape where state and federal law exist in direct conflict.

The Controlled Substances Act and Schedule I Classification (1970)

The Controlled Substances Act of 1970 established the framework that still governs federal drug policy. Cannabis was placed in Schedule I under 21 U.S.C. § 812(c), defined as substances with high potential for abuse, no currently accepted medical use, and lack of accepted safety for use under medical supervision. This classification made cultivation, distribution, and possession federal felonies under 21 U.S.C. § 841, with penalties including up to life imprisonment for large-scale operations. The Schedule I classification created a paradox that persists today: states can remove criminal penalties under their own law, but cannot authorize conduct that remains a federal felony. This tension between state and federal authority has defined cannabis policy for three decades.

California Proposition 215 and the Medical Cannabis Era (1996-2012)

California voters approved Proposition 215 in 1996, establishing the nation's first medical cannabis program. The Compassionate Use Act allowed patients with physician recommendations to possess and cultivate cannabis for medical purposes, directly conflicting with federal prohibition. The federal response was immediate and aggressive. In United States v. Oakland Cannabis Buyers' Cooperative (2001), the Supreme Court held that medical necessity is not a defense to federal cannabis charges under 21 U.S.C. § 841. The DEA conducted hundreds of raids on California dispensaries between 2001 and 2009, seizing property and prosecuting operators under federal law despite state compliance. Gonzales v. Raich (2005) established that Congress has authority under the Commerce Clause to prohibit local cultivation and possession of cannabis, even for medical use in compliance with state law. The decision confirmed that state legalization does not create immunity from federal prosecution, cementing the legal framework that continues today.

The Ogden and Cole Memoranda (2009-2018)

The Obama administration DOJ issued the Ogden Memorandum in October 2009, stating that federal resources should not focus on individuals whose conduct is in "clear and unambiguous compliance" with state medical cannabis laws. While not binding policy, the memo signaled prosecutorial discretion favoring state-compliant operators. The Cole Memorandum, issued in August 2013 after Colorado and Washington legalized adult-use cannabis, formalized DOJ enforcement priorities. Deputy Attorney General James Cole outlined eight priorities, including preventing distribution to minors, preventing revenue from going to criminal enterprises, and preventing diversion to states where cannabis remains illegal. Operators complying with "strong and effective" state regulatory systems would not be federal enforcement priorities. The Cole Memo enabled the modern cannabis industry. Investment capital flowed into state-legal markets, with over $5 billion invested between 2014 and 2017. By 2018, 30 states had medical programs and 9 had legalized adult use, serving a combined market of over 200 million people.

The Sessions Rescission (2018)

Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, returning enforcement decisions to individual U.S. Attorneys. The Sessions Memorandum stated that federal law prohibits cannabis cultivation, distribution, and possession, and that prosecutors should follow established principles in setting priorities and allocating resources. Despite fears of a federal crackdown, prosecutions of state-compliant operators remained rare. U.S. Attorneys in states with legal cannabis programs generally continued the Cole Memo approach, focusing resources on black market operations and interstate trafficking. The industry continued expanding, with legal sales reaching $17.5 billion in 2020.

Congressional Appropriations Riders (2014-Present)

Congress has included provisions in annual appropriations bills since 2014 prohibiting DOJ from using funds to prevent states from implementing medical cannabis laws. The Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer) does not legalize medical cannabis or prevent prosecution of individuals, but restricts DOJ from interfering with state medical programs. In United States v. McIntosh (2016), the Ninth Circuit held that the rider prevents DOJ from prosecuting individuals whose conduct is permitted under state medical cannabis law and who strictly comply with state law. This created a narrow safe harbor for medical operators in full state compliance, though the protection requires annual congressional renewal.

The Biden Administration and Rescheduling (2021-Present)

President Biden directed HHS and DOJ to review cannabis scheduling in October 2022. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on accepted medical use and lower abuse potential relative to Schedule I and II substances. The DEA published a Notice of Proposed Rulemaking in May 2024, proposing to reschedule cannabis to Schedule III under 21 U.S.C. § 811(a). The proposal triggered a formal rulemaking process including public comment and administrative hearings. An Administrative Law Judge heard testimony from medical experts, researchers, and industry stakeholders in December 2025 through March 2026. Rescheduling to Schedule III would maintain federal prohibition under 21 U.S.C. § 841 but eliminate the most severe penalties and, critically, allow cannabis businesses to deduct ordinary business expenses under 26 U.S.C. § 280E. The tax change alone would save the industry an estimated $2 billion annually.

The Current Enforcement Shift (2026)

The DOJ enforcement shift referenced in the Ninth Circuit filing represents the latest evolution in federal policy. While details remain limited, the filing suggests DOJ will not prioritize challenges to state licensing programs that include residency requirements, social equity provisions, or competitive application processes—even where such programs arguably violate the dormant Commerce Clause or create barriers to interstate commerce. This approach marks a departure from previous DOJ positions in cases like Rocky Mountain High Brands v. City of Denver, where federal prosecutors argued that local licensing caps violated federal antitrust principles. The new posture suggests DOJ views state regulatory experimentation as consistent with federalism principles, even where specific program features create legal tensions.

Key Players

Department of Justice

The DOJ sets federal enforcement priorities through internal memoranda, U.S. Attorney guidance, and litigation positions. Attorney General Merrick Garland has emphasized prosecutorial discretion and resource allocation focused on violent crime and organized criminal enterprises. The DOJ's position in the Los Angeles licensing case signals that cannabis enforcement will not target state-compliant operators or challenge state regulatory frameworks absent compelling federal interests like interstate diversion or organized crime involvement.

Drug Enforcement Administration

The DEA administers the Controlled Substances Act and controls scheduling decisions under 21 U.S.C. § 811. The agency's proposed rescheduling to Schedule III represents a historic shift in federal cannabis policy, though the DEA has emphasized that rescheduling does not legalize cannabis or prevent prosecution under federal law. DEA Administrator Anne Milgram testified before Congress in February 2026 that the agency would continue targeting unlicensed cultivation and interstate trafficking regardless of scheduling changes.

City of Los Angeles

Los Angeles implemented a social equity cannabis licensing program in 2018, prioritizing applicants from communities with high cannabis arrest rates prior to legalization. The program includes residency requirements, ownership verification, and competitive scoring criteria. Over 400 social equity applicants have received provisional licenses, though many face challenges securing capital and real estate due to federal illegality. The city has defended its program against Commerce Clause challenges, arguing that local licensing authority is a core police power reserved to municipalities under California law.

Multi-State Operators

MSOs including Curaleaf, Green Thumb Industries, Trulieve, and Verano operate in 10-20 states each, with combined revenues exceeding $10 billion annually. These operators have structured complex corporate arrangements to comply with state laws while managing federal risk, including separate state-level subsidiaries and management services agreements. The DOJ enforcement shift reduces regulatory risk for MSO expansion strategies, particularly in newly legal states like Ohio and Kentucky where operators are competing for limited licenses.

Social Equity Applicants

Social equity programs in Los Angeles, Oakland, San Francisco, Illinois, Massachusetts, New York, and New Jersey prioritize license applicants from communities disproportionately impacted by cannabis prohibition. These applicants often lack access to capital due to federal banking restrictions and face competition from well-funded MSOs. DOJ enforcement policy directly impacts whether social equity programs can operate as intended or face legal challenges based on residency requirements and competitive barriers.

National Cannabis Industry Association

The NCIA represents over 1,500 cannabis businesses and advocates for federal policy reform. The organization has filed amicus briefs supporting state regulatory authority and opposing federal preemption arguments in cases involving banking access, tax treatment under 26 U.S.C. § 280E, and trademark protection. NCIA has emphasized that clear DOJ enforcement guidance is essential for industry stability and investment.

Legal and Regulatory Framework

The federal-state conflict in cannabis regulation creates a complex legal framework where operators must navigate overlapping and contradictory requirements. The Controlled Substances Act remains the foundational federal statute. Under 21 U.S.C. § 841(a)(1), it is unlawful to manufacture, distribute, or possess with intent to distribute a controlled substance. Cannabis remains a Schedule I substance (pending rescheduling), making all cultivation, distribution, and possession federal felonies. Penalties under 21 U.S.C. § 841(b) range from 5 years to life imprisonment depending on quantity, with mandatory minimums for operations involving 100 kilograms or more. The Supremacy Clause in Article VI of the Constitution establishes that federal law preempts conflicting state law. However, the anti-commandeering doctrine prevents the federal government from requiring states to enforce federal law. States can remove criminal penalties under their own law, but cannot authorize conduct that violates federal law or prevent federal prosecution of individuals. The dormant Commerce Clause prohibits states from discriminating against interstate commerce or imposing undue burdens on interstate trade. Cannabis licensing programs with residency requirements, in-state cultivation mandates, or restrictions on out-of-state ownership arguably violate dormant Commerce Clause principles. However, courts have been reluctant to apply Commerce Clause scrutiny to cannabis regulations given that the underlying conduct remains federally illegal. The Rohrabacher-Blumenauer Amendment, included in annual appropriations since 2014, prohibits DOJ from using funds "to prevent" states from implementing medical cannabis laws. The Ninth Circuit interpreted this in United States v. McIntosh to bar prosecution of individuals in strict compliance with state medical cannabis law. The protection is narrow, applies only to medical programs, requires annual renewal, and does not prevent prosecution for conduct outside state law. 26 U.S.C. § 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Cannabis businesses can deduct cost of goods sold but not rent, salaries, marketing, or other operating expenses, resulting in effective federal tax rates of 60-80%. Rescheduling to Schedule III would eliminate 280E application, saving the industry an estimated $2 billion annually. The Bank Secrecy Act and anti-money laundering regulations create barriers to financial services. Banks serving cannabis clients must file Marijuana-Related Business Suspicious Activity Reports with FinCEN and implement enhanced due diligence. Most major banks decline cannabis clients due to federal illegality, forcing operators to rely on credit unions and state-chartered banks willing to accept the compliance burden. State regulatory frameworks vary significantly. California requires state licenses for cultivation, manufacturing, distribution, testing, and retail, with local approval required before state licensing. Illinois uses a competitive application process with social equity scoring. Oklahoma has an open licensing system with minimal barriers to entry. New York awards licenses through a competitive process prioritizing social equity applicants and nonprofit organizations.

State-by-State Breakdown

Cannabis policy varies dramatically across states, creating a patchwork of regulatory approaches that operators must navigate.

California

California operates the nation's largest cannabis market, with $5.3 billion in legal sales in 2025. The state requires separate licenses for cultivation, manufacturing, distribution, testing, and retail under the Medicinal and Adult-Use Cannabis Regulation and Safety Act. Local approval is required before state licensing, and many jurisdictions ban commercial cannabis activity. Possession limit is 28.5 grams for adults 21+. Los Angeles, San Francisco, Oakland, and other cities have implemented social equity programs prioritizing applicants from communities with high pre-legalization arrest rates.

Colorado

Colorado legalized adult use in 2012, becoming one of the first two states with legal recreational markets. The state uses a tiered licensing system with separate licenses for cultivation, manufacturing, testing, and retail. Vertical integration is permitted but not required. Possession limit is 28 grams for adults 21+. The state collected $423 million in cannabis tax revenue in 2025, funding education, infrastructure, and substance abuse prevention programs.

Illinois

Illinois legalized adult use in 2020 with a competitive licensing system that prioritizes social equity applicants. The state awarded 185 dispensary licenses through a lottery system in 2021, with 55% reserved for social equity applicants. Craft grow and infuser licenses are also available. Possession limit is 30 grams for residents, 15 grams for non-residents. The state collected $445 million in cannabis tax revenue in 2025.

Massachusetts

Massachusetts legalized adult use in 2016, with sales beginning in 2018. The state Cannabis Control Commission oversees licensing for cultivation, manufacturing, testing, and retail. Municipalities can opt out of allowing commercial cannabis activity through local ballot measures. The state has implemented economic empowerment and social equity programs providing technical assistance and priority licensing review for qualifying applicants. Possession limit is 28 grams for adults 21+.

Michigan

Michigan legalized adult use in 2018, with sales beginning in 2019. The state uses an open licensing system with separate licenses for cultivation, processing, testing, and retail. Municipalities can opt out through local ordinance. The state has issued over 1,800 licenses across all categories. Possession limit is 71 grams for adults 21+. Michigan collected $290 million in cannabis tax revenue in 2025.

New York

New York legalized adult use in 2021, with the first legal sales beginning in December 2022. The state Office of Cannabis Management oversees licensing through a competitive application process. The Conditional Adult-Use Retail Dispensary program prioritizes applicants with prior cannabis convictions and nonprofit organizations. The state has issued over 200 retail licenses as of August 2026. Possession limit is 85 grams for adults 21+.

Ohio

Ohio voters approved adult-use legalization in November 2023, with sales beginning in August 2024. The state Division of Cannabis Control oversees licensing for cultivation, processing, testing, and retail. Existing medical dispensaries received first priority for adult-use licenses. Possession limit is 71 grams for adults 21+. The state is projected to collect $350 million in cannabis tax revenue in 2026.

Florida

Florida operates a medical-only program established in 2016. The state Department of Health oversees vertically integrated Medical Marijuana Treatment Centers that handle cultivation, processing, and retail. The state has issued 25 MMTC licenses. Voters will consider an adult-use legalization initiative in November 2026. Approximately 890,000 patients are registered in the medical program as of August 2026.

Texas

Texas operates a limited medical program restricted to low-THC cannabis (0.5% THC or less) for specific qualifying conditions. The state Department of Public Safety oversees three licensed dispensing organizations. Possession of recreational cannabis remains a criminal offense, with penalties ranging from Class B misdemeanor (up to 2 ounces) to felony charges for larger amounts.

Market and Business Implications

The DOJ enforcement shift has immediate implications for cannabis business valuations, capital allocation, and strategic planning across the $30 billion U.S. market. MSO expansion strategies depend on regulatory risk assessment. Operators evaluating entry into newly legal states like Ohio and Kentucky weigh state licensing requirements against federal prosecution risk. Clear DOJ guidance that state-compliant operators will not face federal enforcement reduces risk premiums and enables more aggressive expansion. Curaleaf, the nation's largest MSO with operations in 18 states, has stated that federal enforcement clarity is the single most important factor in capital allocation decisions. Valuations for publicly traded cannabis companies correlate directly with federal policy signals. The Canadian Securities Exchange Cannabis Index increased 23% in the week following the May 2024 DEA rescheduling proposal, adding over $3 billion in market capitalization. A formal DOJ policy of non-interference with state-compliant operators would likely trigger similar valuation increases, particularly for MSOs with diversified state portfolios. Banking access remains the most significant operational challenge for cannabis businesses. Approximately 800 financial institutions serve cannabis clients, but most major banks decline the sector due to federal illegality and Bank Secrecy Act compliance requirements. The DOJ enforcement shift does not directly address banking barriers, but reduces prosecution risk for financial institutions serving state-compliant operators. The SAFE Banking Act, which would provide a federal safe harbor for banks serving cannabis clients, has passed the House seven times but has not advanced in the Senate. 280E tax treatment costs the industry an estimated $2 billion annually. Cannabis businesses cannot deduct ordinary business expenses under 26 U.S.C. § 280E, resulting in effective federal tax rates of 60-80%. Rescheduling to Schedule III would eliminate 280E application, dramatically improving profitability for operators. A typical dispensary with $5 million in revenue and $3 million in operating expenses currently pays federal tax on $5 million (minus cost of goods sold only). After rescheduling, the same dispensary would pay federal tax on $2 million in net income, reducing tax liability by approximately $600,000 annually. Wholesale pricing reflects federal risk premiums. Cultivators selling to distributors and manufacturers factor federal prosecution risk into pricing, with risk premiums estimated at 15-25% of wholesale price. Clear DOJ enforcement guidance would reduce these premiums, lowering costs throughout the supply chain and potentially reducing retail prices by 10-15%. Interstate commerce remains prohibited under federal law, requiring each state to maintain a closed-loop supply chain. This creates inefficiencies and prevents economies of scale. California cultivators cannot sell surplus inventory to undersupplied markets in Illinois or New York. Rescheduling to Schedule III does not authorize interstate commerce, but reduces federal penalties for violations and may enable future congressional action to permit interstate trade. Social equity programs depend on federal non-interference. Los Angeles, Oakland, Illinois, Massachusetts, and New York have prioritized license applicants from communities disproportionately impacted by cannabis prohibition. These programs include residency requirements, ownership verification, and competitive scoring criteria that arguably violate the dormant Commerce Clause. The DOJ enforcement shift suggests federal prosecutors will not challenge these programs, enabling continued experimentation with equity-focused licensing.

What Experts Say

Legal scholars, industry analysts, and policy advocates have offered varied assessments of the DOJ enforcement shift and its implications for federal cannabis policy. According to Sam Kamin, professor of marijuana law and policy at the University of Denver Sturm College of Law, the DOJ's position in the Los Angeles licensing case represents a pragmatic approach to federalism in drug policy. Kamin noted that federal prosecutors have limited resources and must prioritize enforcement actions that serve compelling federal interests. State licensing disputes over social equity provisions and residency requirements do not implicate the core federal concerns that justified the Cole Memorandum's enforcement priorities, such as preventing diversion to minors or interstate trafficking. Robert Mikos, professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," has emphasized that DOJ enforcement discretion does not change the underlying legal framework. State-compliant operators remain technically in violation of 21 U.S.C. § 841, and prosecutorial forbearance can be revoked by future administrations. Mikos has argued that only congressional action to deschedule cannabis or create a federal safe harbor for state-compliant conduct can provide true legal certainty. The Marijuana Policy Project, a national advocacy organization, released a statement in August 2026 characterizing the DOJ shift as a positive development for state regulatory programs but insufficient to address the fundamental federal-state conflict. According to the organization's executive director, the enforcement shift reduces immediate prosecution risk but does not resolve banking barriers, 280E tax treatment, or restrictions on interstate commerce that continue to hamper the legal industry. Industry analysts at Cowen & Company issued a research note in August 2026 projecting that the DOJ enforcement shift would add 5-8% to MSO valuations by reducing regulatory risk premiums. The analysis noted that investors have historically discounted cannabis equity valuations by 20-30% relative to comparable consumer packaged goods companies due to federal illegality. Clear DOJ guidance that state-compliant operators will not face federal prosecution reduces this discount, though significant uncertainty remains until Congress acts to deschedule or the DEA completes rescheduling. According to Hilary Bricken, attorney at Harris Bricken and editor of the Canna Law Blog, the Los Angeles licensing case illustrates the complex interplay between federal enforcement policy and state regulatory authority. Bricken noted that dormant Commerce Clause challenges to state licensing programs have generally failed because courts are reluctant to apply Commerce Clause scrutiny to markets involving federally illegal products. The DOJ's decision not to support Commerce Clause challenges to social equity programs suggests federal prosecutors view state experimentation with equity-focused licensing as consistent with broader criminal justice reform goals. The National Organization for the Reform of Marijuana Laws issued a statement emphasizing that prosecutorial discretion is not a substitute for legislative reform. According to NORML's deputy director, the DOJ enforcement shift provides temporary relief for state-compliant operators but can be reversed by future administrations. The organization continues to advocate for the Cannabis Administration and Opportunity Act, which would deschedule cannabis and establish a federal regulatory framework similar to alcohol.

What's Next

The DOJ enforcement shift sets the stage for continued federal-state policy evolution, with key decision points in rescheduling proceedings, congressional legislation, and ongoing litigation. The DEA rescheduling process is expected to conclude by December 2026. The Administrative Law Judge hearing testimony through March 2026 will issue a recommended decision to the DEA Administrator, who will make the final scheduling determination. If the DEA reschedules cannabis to Schedule III, the change would take effect 30 days after publication in the Federal Register. Industry observers expect legal challenges from both opponents arguing the change goes too far and advocates arguing it does not go far enough. Congressional action on cannabis reform remains uncertain. The Cannabis Administration and Opportunity Act, which would deschedule cannabis and establish a federal regulatory framework, has 23 Senate cosponsors but has not advanced to a floor vote. The SAFE Banking Act has passed the House seven times but faces opposition in the Senate from members who argue that banking reform should be paired with broader social equity provisions. The 2026 midterm elections may shift the political calculus, particularly if cannabis legalization initiatives in Florida, North Dakota, and South Dakota succeed in November 2026. The Los Angeles licensing case before the Ninth Circuit will test the scope of DOJ's enforcement shift. Oral arguments are scheduled for October 2026, with a decision expected in early 2027. The case will clarify whether federal courts will apply dormant Commerce Clause scrutiny to state licensing programs with residency requirements and social equity provisions, and whether DOJ's enforcement position influences that analysis. State-level legalization continues to expand. Florida voters will consider an adult-use initiative in November 2026, which would create the nation's third-largest legal market after California and New York. North Dakota and South Dakota also have legalization measures on the November 2026 ballot. Pennsylvania, Minnesota, and Kentucky have active legislative efforts to legalize adult use in 2027. Banking reform may advance through regulatory channels even without congressional action. The Federal Reserve, FDIC, and OCC issued joint guidance in 2023 clarifying that banks serving cannabis clients are not automatically considered high-risk, but most major banks continue to decline the sector. The DOJ enforcement shift may encourage financial regulators to issue additional guidance reducing compliance burdens for banks serving state-compliant operators. Interstate commerce remains prohibited but may become politically viable if rescheduling succeeds. Several bills introduced in Congress would authorize interstate cannabis commerce under a federal regulatory framework similar to alcohol. The U.S. Cannabis Council, representing MSOs and ancillary businesses, has advocated for interstate commerce as essential to industry efficiency and consumer access.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024) — https://www.federalregister.gov/documents/2024/05/21/2024-10636/schedules-of-controlled-substances-rescheduling-of-marijuana
• Cole Memorandum (August 2013) — https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
• United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016) — https://cdn.ca9.uscourts.gov/datastore/opinions/2016/08/16/15-10117.pdf
• Gonzales v. Raich, 545 U.S. 1 (2005) — https://supreme.justia.com/cases/federal/us/545/1/
• HHS Recommendation to Reschedule Cannabis (August 2023) — https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• FinCEN Marijuana Banking Guidance (February 2014) — https://www.fincen.gov/sites/default/files/shared/FIN-2014-G001.pdf
• California Department of Cannabis Control — https://cannabis.ca.gov/
• National Conference of State Legislatures Cannabis Overview — https://www.ncsl.org/health/state-medical-cannabis-laws
• Marijuana Policy Project State Policy Database — https://www.mpp.org/states/